Nexentis Technologies Inc Dossier
Qualitative Analysis
Business overview
Nexentis Technologies Inc. (formerly known as N2OFF, Inc. and Save Foods, Inc.) is a Nasdaq-listed operating company that has transitioned from its agricultural-technology roots into an AI and data-driven computational biotechnology platform focused on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. The company conducts its primary biotechnology operations through its wholly owned subsidiary, MitoCareX Bio Ltd., which targets the mitochondrial SLC25 carrier family to develop first-in-class small-molecule therapeutics. MitoCareX's discovery pipeline is powered by MITOLINE™, a proprietary computational platform designed for the 3D homology modeling of mitochondrial membrane transport proteins. Alongside its core biotech focus, Nexentis maintains an investment strategy in European renewable energy assets utilizing a Ready to Build (RTB) business model, and controls approximately 98% of Save Foods Ltd., which develops post-harvest treatment technologies to reduce pathogen contamination in fresh produce.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the company's core focus from agricultural clean technologies to biotechnology drug discovery, primarily driven by the acquisition of MitoCareX Bio Ltd. and its proprietary MITOLINE computational platform.
Expected impact: Establishing a pipeline of first-in-class small-molecule therapeutics targeting mitochondrial SLC25 transport proteins for cancer and inflammatory metabolic diseases.
Investing in European renewable energy assets utilizing a Ready to Build (RTB) business model to generate capital and support biotechnology operations.
Expected impact: Providing financial flexibility and non-dilutive funding through project development and partial monetization.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire 100% ownership of MitoCareX Bio Ltd., securing its proprietary MITOLINE computational platform and establishing a core business segment focused on mitochondrial drug discovery for cancer and inflammatory metabolic diseases.
Financial impact: Shifted the company's primary business segment and asset base toward biotechnology, driving subsequent R&D expenses and capital raises.
Strategic Partnerships
High. Combines MitoCareX's MITOLINE biological and structural insights with Boltz's biomolecular foundation models to accelerate virtual screening and hit identification for solute carrier (SLC) proteins.
Terms: Not explicitly disclosed.